Psyence Biomedical(PBM)
$3.15+0.06 (+1.78%)
PBM
Psyence Biomedical financials statements
$3.15
At close:+0.06 (+1.78%)
Psyence Biomedical (PBM) Ratios
280 Followers
Psyence Biomedical Ratios
PBM's free cash flow for Q3 2023 was C$-665.00. For the 2023 fiscal year, PBM's free cash flow was decreased by C$-4.00 and operating cash flow was C$-662.00. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 14.62 | 11.04 | 0.09 | 0.08 | 5.59 |
| Quick Ratio | 14.62 | 11.04 | 0.09 | 0.08 | 5.86 |
| Cash Ratio | 11.95 | 10.32 | 0.06 | 0.00 | 3.03 |
| Solvency Ratio | -11.12 | 1.71 | -4.23 | 0.56 | 0.62 |
| Operating Cash Flow Ratio | -13.07 | -6.28 | -0.24 | -0.04 | -5.88 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | -0.28 | -0.76 | 0.00 |
| Net Current Asset Value | C$ 8.49M | C$ 5.97M | C$ -10.98M | C$ -13.07M | C$ -15.58M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 9.23 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | -0.95 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | -19.91 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.04 | 1.09 | -0.10 | 1.06 | 1.08 |
| Debt Service Coverage Ratio | -726.91 | 110.61 | -4.87 | -1.89 | 0.00 |
| Interest Coverage Ratio | -655.06 | -395.15 | -51.98 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.02 | 0.02 | 1.61 | 0.02 | 0.00 |
| Net Debt to EBITDA | 1.08 | -5.98 | -0.19 | -0.52 | 1.29 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 111.20% | -27.62% | 1859.10% | -619.35% | -2462.07% |
| Return on Assets (ROA) | -39.48% | 13.83% | -4518.72% | 3.10% | 3.21% |
| Return on Equity (ROE) | -40.94% | 15.05% | 466.25% | 3.28% | 3.48% |
| Return on Capital Employed (ROCE) | -36.81% | -54.49% | 25.08% | -0.53% | -0.13% |
| Return on Invested Capital (ROIC) | -36.81% | -54.49% | 524.51% | -0.53% | -0.13% |
| Return on Tangible Assets | -39.48% | 13.83% | -4518.72% | 3.10% | 3.21% |
| Earnings Yield | -510.55% | 7.07% | -1.31% | 0.00% | 0.01% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.02 | 0.02 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -15907.86 | -22400.89 | -855243.67 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 15907.86 | 22400.89 | 855243.67 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -14.74 | -6.57 | -0.45 | -0.02 | -0.03 |
| Free Cash Flow Per Share | -15.65 | -6.59 | -0.45 | -0.02 | -0.03 |
| Dividend Paid and CapEx Coverage Ratio | -16.28 | -378.07 | -514.29 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | -16.28 | -378.07 | -514.29 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | -0.28 | -0.76 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -636.18% | -26.16% | -0.08% | -0.00% | -0.00% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.20 | 14.16 | -76.24 | 20539.78 | 18502.39 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.08 | 2.13 | -355.48 | 672.82 | 643.51 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.16 | -3.82 | -1321.73 | -316803.88 | -181467.74 |
| Price-to-Operating Cash Flow Ratio | -0.17 | -3.83 | -1324.30 | -316803.88 | -181467.74 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | -0.12 | -0.07 | -57.70 | 0.00 |
| Enterprise Value Multiple | 0.88 | 7.98 | -76.51 | -127214.42 | -455539.80 |
| Enterprise Value | -6.09M | 8.18M | 3.91B | 164.61B | 152.28B |
| EV to EBITDA | 0.88 | 7.98 | -76.51 | -127214.42 | -455539.80 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | 0.70 | -2.18 | -1325.01 | -316805.17 | -181467.23 |
| EV to Operating Cash Flow | 0.75 | -2.19 | -1327.59 | -316805.17 | -181467.23 |
| Tangible Book Value Per Share | 30.68 | 11.83 | -1.68 | 7.49 | 7.34 |
| Shareholders’ Equity Per Share | 30.68 | 11.83 | -1.68 | 7.49 | 7.24 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -12.56 | 1.78 | -7.85 | 0.25 | 0.25 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 0.99 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.17 | -3.69 | 0.06 | 21.22 | 0.45 |
Currency in CAD

